drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Off-the-shelf, allogeneic T cells genetically modified to express a 4SCAR chimeric antigen receptor targeting BCMA (TNFRSF17), providing CD3ζ signaling with co-stimulation to mediate targeted cytotoxicity and cytokine release against multiple myeloma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Off-the-shelf allogeneic T cells engineered to express a 4SCAR chimeric antigen receptor that binds BCMA (TNFRSF17). Antigen engagement delivers CD3ζ activation with co-stimulation, driving T-cell activation, proliferation, cytokine release, and cytolytic killing of BCMA-positive multiple myeloma cells.
drug_name
Universal allogeneic anti-BCMA 4SCAR T cells
nct_id_drug_ref
NCT06006741